P Ragnhammar

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi A systematic overview of chemotherapy effects in colorectal cancer
    P Ragnhammar
    Radiumhemmet, Stockholm, Sweden
    Acta Oncol 40:282-308. 2001
  2. ncbi A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence
    P Ragnhammar
    Radiumhemmet, Stockholm, Sweden
    Acta Oncol 40:391-411. 2001
  3. ncbi Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors
    H Mellstedt
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Curr Opin Hematol 6:169-75. 1999
  4. ncbi Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
    D Edler
    Department of Surgery, South Hospital, Stockholm, Sweden
    Clin Cancer Res 6:1378-84. 2000
  5. ncbi A systematic overview of chemotherapy effects in urothelial bladder cancer
    S Nilsson
    Radiumhemmet, Stockholm, Sweden
    Acta Oncol 40:371-90. 2001
  6. ncbi Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma
    H Mellstedt
    Cancer Centre Karolinska, Department of Oncology, Karolinska Hospital Karolinska Institute, Stockholm, Sweden
    Ann N Y Acad Sci 910:254-61; discussion 261-2. 2000

Detail Information

Publications6

  1. ncbi A systematic overview of chemotherapy effects in colorectal cancer
    P Ragnhammar
    Radiumhemmet, Stockholm, Sweden
    Acta Oncol 40:282-308. 2001
    ..The role of these agents, alone or in combinations, in clinical routine remains, however, to be determined due to more pronounced toxicity than caused b..
  2. ncbi A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence
    P Ragnhammar
    Radiumhemmet, Stockholm, Sweden
    Acta Oncol 40:391-411. 2001
    ..by not discontinuing treatment despite the absence of clinical benefits. Likewise, one cannot exclude the possibility of underutilisation, e.g. by patients declining treatment because they were not informed about the potential benefits...
  3. ncbi Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors
    H Mellstedt
    Department of Oncology Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Curr Opin Hematol 6:169-75. 1999
    ..It is urgently warranted to better understand these dual effects on the immune system so that we can find optimal uses for the growth factors in various clinical settings...
  4. ncbi Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
    D Edler
    Department of Surgery, South Hospital, Stockholm, Sweden
    Clin Cancer Res 6:1378-84. 2000
    ..Patients with low intratumoral TS expression had a significantly better outcome than those with high TS expression...
  5. ncbi A systematic overview of chemotherapy effects in urothelial bladder cancer
    S Nilsson
    Radiumhemmet, Stockholm, Sweden
    Acta Oncol 40:371-90. 2001
    ....
  6. ncbi Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma
    H Mellstedt
    Cancer Centre Karolinska, Department of Oncology, Karolinska Hospital Karolinska Institute, Stockholm, Sweden
    Ann N Y Acad Sci 910:254-61; discussion 261-2. 2000
    ..A strong type I T cell response was induced that seemed to be MHC class I as well as class II restricted. No systemic side effects were noted...